[Comprehensive therapy for @entity1 @entity5 associated with XXXX ].

@entity1 @entity5 @entity5935 @entity16970 @entity1003 @entity1891 @entity285 @entity968 @entity288
OBJECTIVE: To summarize the management of @entity1 @entity5 with @entity16970 ( @entity16970 ) and to evaluate the effect of drug combined with sclerotherapy. METHODS: From Feb. 2007 to Nov. 2014, 25 cases with @entity16970 , who underwent drug therapy combined with sclerotherapy, were retrospectively studied. Oral @entity288 (2 mg/kg per day) was used as the first-line therapy on all of the @entity1 and intravenous @entity1891 (1.5 mg/m2 every week) was added when the platelet counts didn't recover obviously after 2-3 weeks. After the recovery of the platelet counts, the @entity1 were admitted for sclerotherapy (average, 4.56 sessions per case) with 100% @entity285 (1-3 ml per session), @entity968 (1.25-5 ml per session) and @entity5935 (0.25-1 ml per session). All the @entity1 were followed up for 42 months ( range, 9 months to 6.5 years). Therapeutic outcomes were assessed by evaluating platelet counts, size of lesion, function of trunk and limb. RESULTS: All the 25 cases got obvious recovery in the platelet counts [average, (94.3    18.5) x 10(9)/L] after drug therapy, of which 16 were treated by single oral @entity288 for 4-7 weeks and 9 were treated by @entity288 plus intravenous @entity1891 for 2-5 weeks. Meantime, 11 cases received platelet transfusions, of which 3 were coupled with gamma globulin intramuscularly. During the first admission, each of the 25 cases received 1-4 sessions of sclerotherapy (average, 2.6 sessions each case). One week after the sclerotherapy, the platelet counts returned to (167-312) x 10(9)/L (average, (258.5    34.4) x 10(9)/L). The hemoglobin and @entity1003 function returned to normal within 1-5 weeks. Meanwhile the mental condition, appetite, body weight, sleeping were greatly improved. The size of the lesions decreased gradually after the combined therapy including 13 cases within 3-12 months and 13 cases within 13-36 months. Long term follow-up indicated that only 1 case need treatment for recurrent decrease of platelet counts, and all of the 25 cases kept the normal weight, height, immunity as well as the growing development. CONCLUSIONS: Oral @entity288 plus intravenous @entity1891 combined with sclerotherapy is a reliable management with high cure rate, short course and minor side-effect.
